Dallas, Texas 02/10/2014 (FINANCIALSTRENDS) – There are many investment and trading firms who are telling different investors and traders to keep a hawk eye on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) and probable the main reason behind this advice is the recent agreement that has happened between GW Pharmaceuticals and a French pharmaceutical company called as Ipsen. The agreement is related to the promotion and distribution of Sativex which is basically a controversial cannabis spray in Latin America that also includes Mexico and Caribbean Islands.
Sativex is the same drug that is also used for treating spasticity in multiple sclerosis cases. Currently this drug is approved in 24 different countries that are primarily European countries. Now GW Pharmaceuticals and Ipsen both are trying to expand their operations into the North America and for capturing this market both of these companies have partnered with Otsuka Pharmaceuticals. The main aim of the company is to clear the phase 3 trails.
An Overview of the Company
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is basically a Pharmaceutical company that is primarily engaged into development, discovery and commercialization of medicines and drugs that are based on Cannabis. The company operates through it three subsidiaries namely Sativex Commercial, Sativex Research and Development and Pipeline Research and Development.
The last trading session saw an above normal volume of 119,627.00 shares and the stock finally closed at $5.00. For the entire trading session the share price kept on hovering between $4.61 and $5.05. If we talk about the current market capitalization of GW Pharmaceuticals then it comes out to be $1.01 billion. The 52 week high of this stock is around $5.05 and its 52 week low is $0.58. Its current market capitalization is another reason why many market analysts and trade pundits are quite bullish about this stock and are advising their clients to main a hawk eye on this stock.